Compare BioNTech SE - ADR (BNTX) vs Conagra Brands Inc (CAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Conagra Brands Inc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Conagra Brands Inc trades at $14.11 (market cap $6.77B). The key difference: BioNTech SE - ADR is far larger — about 3.4× Conagra Brands Inc's market cap, and Conagra Brands Inc pays a 9.89% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | CAG | |
|---|---|---|
Market Cap | $22.86B | $6.77B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $20.02 |
52-Week Low | $83.89 | $12.58 |
Enterprise Value | $6.53B | $14.05B |
Dividend Yield | — | 9.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Conagra Brands (CAG) trades at $14.33, up 3.62% today, with a bullish technical signal from moving averages. The stock shows mixed earnings performance, missing Q2 2025 and Q1 2026 estimates but beating Q3 2025. Valuation ratios appear attractive with P/E of 10.06 and P/B of 0.84, though net income margin is negative at -0.39%. Recent news highlights upcoming Q4 earnings and dividend sustainability concerns under new leadership.
CAG presents a high-yield opportunity with a 10% dividend, but faces risks from potential dividend cuts, high debt, and revenue pressures. Analyst consensus is cautious with a $13.70 price target below current levels. Investors should weigh the defensive staple positioning against fundamental headwinds and earnings volatility for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
